Humatrix, a novel myoepithelial matrical gel with unique biochemical and biological properties

被引:19
作者
Kedeshian, P
Sternlicht, MD
Nguyen, M
Shao, ZM
Barsky, SH [1 ]
机构
[1] Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA
[2] Univ Calif Los Angeles, Sch Med, Div Surg Oncol, Los Angeles, CA 90024 USA
关键词
myoepithelial tumors; human matrix-producing xenografts; Humatrix; proteinase inhibition; angiogenesis inhibition; metastasis inhibition;
D O I
10.1016/S0304-3835(97)00429-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Myoepithelial cells in situ and in vitro exert important paracrine effects on carcinoma cells which are mediated by high expression of extracellular matrix molecules, proteinase inhibitors and angiogenic inhibitors. Myoepithelial xenografts (human matrix secreting (HMS)-X, HMS-3X and HMS-4X) established from benign human salivary gland and breast myoepithelial tumors accumulate an abundant extracellular matrix which can be extracted with 6 M urea and 2 M guanidinium hydrochloride to form a gel at 25-37 degrees C. This gel, termed Humatrix, exhibits different biochemical and biological properties than the conventional non-human matrical gels in existence, i.e. Matrigel and Vitrogen 100. Whereas Matrigel consists mainly of basement membrane molecules, e.g. laminin, type IV collagen and heparan sulfate proteoglycan, and Vitrogen 100 consists mainly of non-basement membrane molecules, e.g. type I and type III collagen, Humatrix contains significant amounts of both basement membrane and non-basement membrane molecules, including large amounts of chondroitin sulfate proteoglycan. Like Matrigel, Humatrix contains bound growth factors, including epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I); unlike Matrigel, which contains predominately significant quantities of bound proteinases, including tissue-type plasminogen activator (tPA), matrix metalloproteinase (MMP)-2 and MMP-9, and angiogenic factors, including basic fibroblast growth factor (bFGF) and transforming growth factor (TGF)-beta, Humatrix contains predominately bound proteinase inhibitors such as protease nexin II (PN-II) and alpha 1-antitrypsin and angiogenic inhibitors such as thrombospondin-l. Humatrix selectively stimulates the growth and tumorigenicity of human myoepithelial cell lines but inhibits invasion, angiogenesis and metastasis of other non-myoepithelial malignant cell lines. Because of its myoepithelial origin Humatrix represents a more natural source of extracellular matrix molecules and bound factors that carcinoma cells encounter in vivo. Published by Elsevier Science Ireland Ltd.
引用
收藏
页码:215 / 226
页数:12
相关论文
共 58 条
[1]  
ALBINI A, 1987, CANCER RES, V47, P3239
[2]   PLASMINOGEN-ACTIVATOR INHIBITORS - HORMONALLY REGULATED SERPINS [J].
ANDREASEN, PA ;
GEORG, B ;
LUND, LR ;
RICCIO, A ;
STACEY, SN .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1990, 68 (01) :1-19
[3]  
BARSKY SH, 1988, CANCER, V61, P1798, DOI 10.1002/1097-0142(19880501)61:9<1798::AID-CNCR2820610913>3.0.CO
[4]  
2-G
[5]  
BARSKY SH, 1996, Patent No. 5508188
[6]  
BARSKY SH, 1997, Patent No. 5643787
[7]   THE TURNOVER OF BASAL LAMINA GLYCOSAMINOGLYCAN CORRELATES WITH EPITHELIAL MORPHOGENESIS [J].
BERNFIELD, M ;
BANERJEE, SD .
DEVELOPMENTAL BIOLOGY, 1982, 90 (02) :291-305
[8]   A MODIFIED URONIC ACID CARBAZOLE REACTION [J].
BITTER, T ;
MUIR, HM .
ANALYTICAL BIOCHEMISTRY, 1962, 4 (04) :330-&
[9]  
Cutler L S, 1990, Adv Dent Res, V4, P27
[10]  
Daniels JR, 1976, U.S Patent, Patent No. [3 949073, 3949073]